Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Budigalimab · ABBV-181, PR-1648817

Monoclonal antibody · Antagonist of PD-1 (PDCD1) · developed by AbbVie

Phase 2/3 Most advanced trial
ABBV Developer
1 Registered trials

What is Budigalimab?

Budigalimab is a monoclonal antibody that binds to PD-1 on T cells, blocking its interaction with PD-L1 and restoring immune function against tumors. It is being studied in hepatocellular carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ABBV-181, PR-1648817
Drug type
Monoclonal antibody
Targets
PD-1 (PDCD1)
Mechanism
Antagonist of PD-1 (PDCD1)
Pathways
PD-1/PD-L1 signaling, T-cell activation
Therapy area
Oncology
Developer
AbbVie (ABBV)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
6VDO4TY3OO

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06109272 Phase 2/3 Hepatocellular Carcinoma Active not recruiting ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatocellular Carcinoma

Other drugs acting on PDCD1

Berahyaluronidase Alfa and Pembrolizumab FDA approved Nivolumab FDA approved Pembrolizumab FDA approved Toripalimab FDA approved Atigotatug/Nivolumab Phase 1 Balstilimab Phase 2/3 BPT567 Phase 1 Cadonilimab Early Phase 1 CDX-585 Phase 1 CTX-8371 Phase 1 Geptanolimab Phase 1/2 Ivonescimab Phase 3

More from AbbVie

Adalimumab FDA approved Atogepant FDA approved Pivekimab Sunirine FDA approved Risankizumab FDA approved Telisotuzumab Vedotin FDA approved Upadacitinib FDA approved Venetoclax FDA approved ABBV-1042 Phase 1 ABBV-291 Phase 1 ABBV-295 Phase 2 ABBV-313 Phase 1 ABBV-324 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ABBV page.

Follow ABBV, the company behind Budigalimab

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.